Migraine accounts for many billions of dollars in direct and indirect health care costs, said Peter McAllister, MD, a neurologist, board certified headache specialist, and medical director of the New England Institute for Neurology and Headache.
Migraine accounts for many billions of dollars in direct and indirect health care costs, said Peter McAllister, MD, a neurologist, board certified headache specialist, and medical director of the New England Institute for Neurology and Headache.
Transcript:
The American Journal of Managed Care® (AJMC®): What are some of the economic benefits of migraine prevention?
Dr. McAllister: When you look at the numbers for migraine, it is huge. It's in the many billions of dollars in health care costs and utilization. That can be divided into two buckets, really. There's direct health care costs related to migraine, and that is going to the doctor, going to the emergency department, getting migraine medication. But the much bigger slice of the pie is the indirect costs. That is the missing work, what we call absenteeism, or actually showing up for work, but being so shot from your migraine, that you have difficulty focusing, you're inefficient, and that costs the system billions of dollars. If you can get people to have a whole lot less migraine attacks per month, and then per year, etc., you're going to decrease those indirect costs as well as decrease the direct costs substantially.
A new study highlights significant disparity in reimbursement rates across states between hospitals and Medicare; the first patient to receive a genetically modified pig kidney has died; research examines outcomes of over 500 patients receiving medication abortion pills by mail.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Challenges in developing next-generation cancer therapies persist; research indicates widespread utilization and hurdles in affordability and access to glucagon-like peptide-1 (GLP-1) medications; legislation seeks to legalize therapeutic use of psychedelics in California.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
Medication Adherence Star Ratings Measures, Health Care Resource Utilization, and Cost
May 9th 2024For patients prescribed diabetes, hypertension, and hyperlipidemia medications, nonadherence to CMS Star Ratings quality measures of medication adherence was associated with increased health care resource utilization and costs.
Read More